• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kenvue Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    5/21/25 6:00:31 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email
    kvue-20250520
    0001944048False00019440482025-05-202025-05-20

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): May 20, 2025
    Kenvue Inc.
    (Exact name of registrant as specified in its charter)
    Delaware001-4169788-1032011
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    1 Kenvue Way
    Summit, New Jersey
    07901
    (Address of principal executive offices)(Zip Code)
    Registrant’s telephone number, including area code: (908)-874-1200
    Not applicable
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange
    on which registered
    Common Stock, $0.01 par value per shareKVUENew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 1.01 Entry into a Material Definitive Agreement
    On May 20, 2025, Kenvue Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc. and Deutsche Bank Securities Inc., as Representatives for the several Underwriters (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $750,000,000 aggregate principal amount of the Company’s 4.850% Senior Notes due 2032 in an underwritten public offering (the “Offering”) pursuant to the Company’s registration statement on Form S-3 (Registration File No. 333-285172). The Company intends to use the net proceeds from the Offering for general corporate purposes.
    The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is attached as Exhibit 1.1 hereto and is incorporated herein by reference.
    Cautions Concerning Forward-Looking Statements
    This Current Report on Form 8-K contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the proposed Offering, including the net proceeds therefrom and the use of such proceeds. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning. Readers are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company and its affiliates.
    A list and descriptions of risks, uncertainties and other factors can be found in the Company’s filings with the Securities and Exchange Commission, including its registration statement on Form S-3, Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other filings, available on request from the Company. The Company and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.
    Item 9.01 Financial Statements and Exhibits
    (d)     Exhibits.
    Exhibit Number

    Exhibit Description



    1.1

    Underwriting Agreement dated May 20, 2025, among the Company and Citigroup Global Markets Inc. and Deutsche Bank Securities Inc., as Representatives for the several Underwriters
    104

    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    KENVUE INC.
    Date: May 21, 2025By:/s/ Edward J. Reed
    Name:
    Edward J. Reed
    Title:Vice President, Corporate Secretary

    Get the next $KVUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    9/24/2024$24.00Outperform → Sector Perform
    RBC Capital Mkts
    5/28/2024$21.00Neutral
    Citigroup
    4/11/2024$18.00Underperform
    Bernstein
    More analyst ratings

    $KVUE
    Financials

    Live finance-specific insights

    See more
    • Kenvue Reports First Quarter 2025 Results

      Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p

      5/8/25 6:50:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue to Announce First Quarter 2025 Results on May 8, 2025

      Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine

      4/24/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Declares Quarterly Cash Dividend

      Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend is payable on May 28, 2025, to shareholders of record as of the close of business on May 14, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in

      4/16/25 8:19:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    SEC Filings

    See more
    • Kenvue Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Kenvue Inc. (0001944048) (Filer)

      5/21/25 6:00:31 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form FWP filed by Kenvue Inc.

      FWP - Kenvue Inc. (0001944048) (Subject)

      5/20/25 4:27:10 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 424B5 filed by Kenvue Inc.

      424B5 - Kenvue Inc. (0001944048) (Filer)

      5/20/25 8:45:35 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smith Jeffrey C disposed of 1,124,062 shares (SEC Form 4)

      4 - Kenvue Inc. (0001944048) (Issuer)

      5/16/25 9:32:14 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 3 filed by new insider Banati Amit

      3 - Kenvue Inc. (0001944048) (Issuer)

      5/16/25 4:41:26 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Director Smith Jeffrey C

      4 - Kenvue Inc. (0001944048) (Issuer)

      4/2/25 4:36:01 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference

      Kenvue Inc. (NYSE:KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced the Company's participation in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. Thibaut Mongon, Chief Executive Officer, Amit Banati, Chief Financial Officer, and Carlton Lawson, Group President, Europe, Middle East and Africa & Latin America will participate in a fireside chat on Tuesday, June 3, 2025, at 6:00 a.m. Eastern Time / 12:00 p.m. Central European Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. is the world's larges

      5/21/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities

      Kenvuers contribute 5,000+ hours of volunteer time to local causes along with building 22,000+ hygiene kits for underserved communities Hygiene kits to feature 110,000+ donated products from iconic brands Neutrogena®, Listerine®, OGX®, Johnson's® Baby and more Kenvue Inc. (NYSE:KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced its global community engagement efforts in celebration of Kenvue Cares Week, the company's signature annual volunteer initiative part of its Healthy Lives Mission. Kenvue Cares Week is a testament to the strong Kenvue commitment to advance the well-being of people and our planet, giving back through voluntee

      5/14/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Reports First Quarter 2025 Results

      Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p

      5/8/25 6:50:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Leadership Updates

    Live Leadership Updates

    See more
    • Kenvue Announces Chief Financial Officer Transition

      Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

      5/8/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Announces Three New Appointments to Board of Directors

      Company and Starboard Value LP Enter into Cooperation Agreement Kenvue Inc. (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the appointment of two new independent directors, Sarah Hofstetter, President of Profitero, Ltd., and Erica Mann, former President and Head of Bayer's Consumer Health Division, to the Company's Board of Directors (the "Board"). Additionally, Jeffrey Smith, Managing Member, Chief Executive Officer and Chief Investment Officer of Starboard Value LP (together with certain of its affiliates, "Starboard") will join the Board. All three appointments are effective immediately. "We are pleased to welcome Sarah, Erica and Jeff as

      3/5/25 8:05:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Announces Board Changes with Two New Independent Directors

      Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight. Appointment of Two New Independent Directors to the Boa

      7/31/24 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      11/14/24 1:22:40 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      11/12/24 10:32:12 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      10/16/24 10:07:52 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Kenvue with a new price target

      Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50

      4/10/25 12:41:58 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Evercore ISI initiated coverage on Kenvue with a new price target

      Evercore ISI initiated coverage of Kenvue with a rating of In-line and set a new price target of $25.00

      3/24/25 8:39:49 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously

      1/6/25 8:13:28 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary